Cargando…

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status

BACKGROUND: The potential benefit of risk stratification using a 4-miRNA signature in combination with MGMT promoter methylation in IDH1/2 wild-type glioblastoma patients was assessed. METHODS: Primary tumors from 102 patients with comparable treatment from the LMU Munich (n = 37), the University Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unger, Kristian, Fleischmann, Daniel F, Ruf, Viktoria, Felsberg, Jörg, Piehlmaier, Daniel, Samaga, Daniel, Hess, Julia, Suresh, Marian Preetham, Mittelbronn, Michel, Lauber, Kirsten, Budach, Wilfried, Sabel, Michael, Rödel, Claus, Reifenberger, Guido, Herms, Jochen, Tonn, Jörg-Christian, Zitzelsberger, Horst, Belka, Claus, Niyazi, Maximilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712804/ https://www.ncbi.nlm.nih.gov/pubmed/33305269 http://dx.doi.org/10.1093/noajnl/vdaa137

Ejemplares similares

A 4-miRNA signature predicts the therapeutic outcome of glioblastoma
por: Niyazi, Maximilian, et al.
Publicado: (2016)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
por: Berger, Kerstin, et al.
Publicado: (2020)

Single-center versus multi-center data sets for molecular prognostic modeling: a simulation study
por: Samaga, Daniel, et al.
Publicado: (2020)

Radiotherapy and "new" drugs-new side effects?
por: Niyazi, Maximilian, et al.
Publicado: (2011)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data
por: Schnöller, Leon Emanuel, et al.
Publicado: (2023)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation
por: Brix, Nikko, et al.
Publicado: (2020)

Use of diffusion-weighted MRI to modify radiosurgery planning in brain metastases may reduce local recurrence
por: Zakaria, Rasheed, et al.
Publicado: (2016)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas
por: Hadi, Indrawati, et al.
Publicado: (2021)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status
por: Weller, Jonathan, et al.
Publicado: (2023)

Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients
por: Summerer, Isolde, et al.
Publicado: (2013)

Erratum: Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients
por: Summerer, Isolde, et al.
Publicado: (2015)

Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions
por: Marini, Patrizia, et al.
Publicado: (2009)

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy
por: Manapov, Farkhad, et al.
Publicado: (2013)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine PET
por: Bauer, Elena K., et al.
Publicado: (2020)

Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas
por: Wolter, Marietta, et al.
Publicado: (2022)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

MiRNA expression patterns predict survival in glioblastoma
por: Niyazi, Maximilian, et al.
Publicado: (2011)

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Counting colonies of clonogenic assays by using densitometric software
por: Niyazi, Maximilian, et al.
Publicado: (2007)

Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy
por: Schnöller, Leon Emanuel, et al.
Publicado: (2022)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

Isobologram analysis of triple therapies
por: Niyazi, Maximilian, et al.
Publicado: (2006)

Combination of pre-treatment dynamic [(18)F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
por: Li, Zhicong, et al.
Publicado: (2022)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents
por: Siller, Sebastian, et al.
Publicado: (2021)

Iodine-125 brachytherapy for brain tumours - a review
por: Schwarz, Silke B, et al.
Publicado: (2012)

MicroRNA expression profiles in human cancer cells after ionizing radiation
por: Niemoeller, Olivier M, et al.
Publicado: (2011)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond
por: Orth, Michael, et al.
Publicado: (2021)

Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma
por: Teske, Nico, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k9vhnqkpvqn58mtgphkki1ierl